Global Ear Infection Treatment Market Research Report—Forecast till 2027
出 版 商：Market Research Future
出版日期：2020/12/17
頁 數：137頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
USD 6,250 (Global-User License)
Global Ear Infection Treatment Market Research Report—Forecast till 2027
Market Dynamics
Global Ear Infection Treatment Market is anticipated to witness a healthy CAGR of 4.84% during the review period of 2020 to 2027, to surpass USD 19,370.24 Million by 2027. An ear infection is a common health problem worldwide and is most common in young children and older people. The global market growth is attributed to the growing rate of incidences of ear infection treatment. According to WHO, the rate of incidences of ear infection occurs in children between the ages of 6 and 36 months, which is expected to fuel the global market. However, the disease is more common in the older population is further expected to contribute to the growth of the global market.
The global Ear Infection Treatment Market Research Report is anticipated to witness significant market growth during the review period. Additionally, the increasing rate of incidence has been propelling the growth of the ear infection treatment market in the last few years and is expected to command the market during the review period.
Market Segmentation
Global Ear Infection Treatment Market has been classified based on Type, Pathogen, Treatment, and End User.
Based on the type segment, the Global Ear Infection Treatment Market has been classified into the middle ear, outer ear, inner ear, and others.
This part is mostly affected by an ear infection. In terms of the pathogen, the global ear infection treatment market has been bifurcated into bacteria and viruses. The bacteria segment is contributed a larger market share during the review period owing to the growing ear infection due to bacteria.
The global ear infection treatment market, by treatment, has been categorized into medication and surgery. The medication segment dominated the market. In terms of end-use industry, the global market has been classified into hospitals, ENT clinics, and others.
Regional Analysis
Geographically, Global Ear Infection Treatment Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been classified into North America and Latin America, with the North American market further segmented into the US and Canada. The Americas is likely to command the market owing to the increasing prevalence of ear infection disease and product prevalence of ear infection disease and product innovation in the region.
The European ear infection treatment market has been classified into Western Europe and Eastern Europe. The Western Europe ear infection treatment market has further been segmented into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. Europe is expected to follow the Americas in terms of value during the review period due to the presence of supportive government initiatives, and research and development activities and, various marketing strategies by major market players.
Asia-Pacific is expected to register the fastest-growing market during the review period owing to the rising healthcare expenditure, expansion of enhanced healthcare facilities in China, India, and Australia, and increasing population suffering from ear infections.
Major Players
The Key Players in the Global Ear Infection Treatment Market include Novartis International AG. (Switzerland)., Sanofi S.A (France), Janssen Pharmaceutica (Belgium), Pfizer Inc (US), and Abbott Laboratories (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Market Dynamics
Global Ear Infection Treatment Market is anticipated to witness a healthy CAGR of 4.84% during the review period of 2020 to 2027, to surpass USD 19,370.24 Million by 2027. An ear infection is a common health problem worldwide and is most common in young children and older people. The global market growth is attributed to the growing rate of incidences of ear infection treatment. According to WHO, the rate of incidences of ear infection occurs in children between the ages of 6 and 36 months, which is expected to fuel the global market. However, the disease is more common in the older population is further expected to contribute to the growth of the global market.
The global Ear Infection Treatment Market Research Report is anticipated to witness significant market growth during the review period. Additionally, the increasing rate of incidence has been propelling the growth of the ear infection treatment market in the last few years and is expected to command the market during the review period.
Market Segmentation
Global Ear Infection Treatment Market has been classified based on Type, Pathogen, Treatment, and End User.
Based on the type segment, the Global Ear Infection Treatment Market has been classified into the middle ear, outer ear, inner ear, and others.
This part is mostly affected by an ear infection. In terms of the pathogen, the global ear infection treatment market has been bifurcated into bacteria and viruses. The bacteria segment is contributed a larger market share during the review period owing to the growing ear infection due to bacteria.
The global ear infection treatment market, by treatment, has been categorized into medication and surgery. The medication segment dominated the market. In terms of end-use industry, the global market has been classified into hospitals, ENT clinics, and others.
Regional Analysis
Geographically, Global Ear Infection Treatment Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been classified into North America and Latin America, with the North American market further segmented into the US and Canada. The Americas is likely to command the market owing to the increasing prevalence of ear infection disease and product prevalence of ear infection disease and product innovation in the region.
The European ear infection treatment market has been classified into Western Europe and Eastern Europe. The Western Europe ear infection treatment market has further been segmented into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. Europe is expected to follow the Americas in terms of value during the review period due to the presence of supportive government initiatives, and research and development activities and, various marketing strategies by major market players.
Asia-Pacific is expected to register the fastest-growing market during the review period owing to the rising healthcare expenditure, expansion of enhanced healthcare facilities in China, India, and Australia, and increasing population suffering from ear infections.
Major Players
The Key Players in the Global Ear Infection Treatment Market include Novartis International AG. (Switzerland)., Sanofi S.A (France), Janssen Pharmaceutica (Belgium), Pfizer Inc (US), and Abbott Laboratories (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 16
2.2 RESEARCH OBJECTIVE 16
2.3 MARKET STRUCTURE 16
2.4 ASSUMPTIONS & LIMITATIONS 17
3 RESEARCH METHODOLOGY
3.1 DATA MINING 18
3.2 SECONDARY RESEARCH 19
3.3 PRIMARY RESEARCH 19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 23
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 HIGH RATE OF EAR INFECTIONS 26
4.2.2 INCREASING EXPENDITURE BY GOVERNMENTS ACROSS THE WORLD TOWARDS HEALTHCARE 26
4.2.3 RISE IN RISK FACTORS 26
4.2.4 DRIVERS IMPACT ANALYSIS 27
4.3 RESTRAINTS 27
4.3.1 RISKS AND COMPLICATIONS OF SURGERY 27
4.3.2 EMERGENCE OF BACTERIAL RESISTANCE 27
4.3.3 RESTRAINTS IMPACT ANALYSIS 28
4.4 OPPORTUNITIES 28
4.4.1 TECHNOLOGICAL ADVANCEMENTS IN EAR INFECTION DIAGNOSIS AND SURGERY 28
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D AND DESIGNING 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION 30
5.1.4 MARKETING & SALES 30
5.2 PORTER’S FIVE FORCES MODEL 31
5.2.1 BARGAINING POWER OF SUPPLIERS 32
5.2.2 BARGAINING POWER OF BUYERS 32
5.2.3 THREAT OF NEW ENTRANTS 32
5.2.4 THREAT OF SUBSTITUTES 32
5.2.5 RIVALRY 32
5.3 IMPACT OF COVID-19 33
6 GLOBAL EAR INFECTION TREATMENT MARKET, BY TYPE
6.1 OVERVIEW 34
6.2 MIDDLE EAR 35
6.3 OUTER EAR 35
6.4 INNER EAR 36
7 GLOBAL EAR INFECTION TREATMENT MARKET, BY PATHOGEN
7.1 OVERVIEW 37
7.2 BACTERIA 38
7.3 VIRUS 38
8 GLOBAL EAR INFECTION TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW 39
8.2 SURGERY 40
8.3 MEDICATION 41
9 GLOBAL EAR INFECTION TREATMENT MARKET, BY END USER
9.1 OVERVIEW 43
9.2 HOSPITALS 44
9.3 ENT CLINICS 44
9.4 OTHERS 44
10 GLOBAL EAR INFECTION TREATMENT MARKET, BY REGION
10.1 OVERVIEW 45
10.2 AMERICAS 47
10.2.1 NORTH AMERICA 50
10.2.1.1 US 53
10.2.1.2 CANADA 55
10.2.2 SOUTH AMERICA 57
10.3 EUROPE 59
10.3.1 WESTERN EUROPE 62
10.3.1.1 GERMANY 65
10.3.1.2 FRANCE 67
10.3.1.3 UK 69
10.3.1.4 ITALY 71
10.3.1.5 SPAIN 73
10.3.1.6 REST OF WESTERN EUROPE 75
10.3.2 EASTERN EUROPE 77
10.4 ASIA-PACIFIC 79
10.4.1 CHINA 82
10.4.2 JAPAN 84
10.4.3 INDIA 86
10.4.4 AUSTRALIA 88
10.4.5 SOUTH KOREA 90
10.4.6 REST OF ASIA-PACIFIC 92
10.5 MIDDLE EAST AND AFRICA 94
10.5.1 MIDDLE EAST 97
10.5.2 AFRICA 99
11 COMPANY PROFILES
11.1 NOVARTIS INTERNATIONAL AG 101
11.1.1 COMPANY OVERVIEW 101
11.1.2 FINANCIAL OVERVIEW 102
11.1.3 PRODUCTS/SERVICES OFFERED 103
11.1.4 KEY DEVELOPMENTS 103
11.1.5 SWOT ANALYSIS 104
11.1.6 KEY STRATEGIES 104
?
11.2 SANOFI S.A. 105
11.2.1 COMPANY OVERVIEW 105
11.2.2 FINANCIAL OVERVIEW 106
11.2.3 PRODUCTS/SERVICES OFFERED 106
11.2.4 KEY DEVELOPMENTS 107
11.2.5 SWOT ANALYSIS 107
11.2.6 KEY STRATEGIES 108
11.3 JANSSEN PHARMACEUTICALS 109
11.3.1 COMPANY OVERVIEW 109
11.3.2 FINANCIAL OVERVIEW 110
11.3.3 PRODUCTS/SERVICES OFFERED 110
11.3.4 KEY DEVELOPMENTS 111
11.3.5 SWOT ANALYSIS 111
11.3.6 KEY STRATEGIES 111
11.4 PFIZER INC. 112
11.4.1 COMPANY OVERVIEW 112
11.4.2 FINANCIAL OVERVIEW 113
11.4.3 PRODUCTS/SERVICES OFFERED 113
11.4.4 KEY DEVELOPMENTS 114
11.4.5 SWOT ANALYSIS 114
11.4.6 KEY STRATEGIES 114
11.5 ABBOTT LABORATORIES 115
11.5.1 COMPANY OVERVIEW 115
11.5.2 FINANCIAL OVERVIEW 116
11.5.3 PRODUCTS/SERVICES OFFERED 116
11.5.4 KEY DEVELOPMENTS 117
11.5.5 SWOT ANALYSIS 117
11.5.6 KEY STRATEGIES 117
11.6 SUN PHARMACEUTICAL INDUSTRIES LIMITED 118
11.6.1 COMPANY OVERVIEW 118
11.6.2 FINANCIAL OVERVIEW 119
11.6.3 PRODUCTS/SERVICES OFFERED 120
11.6.4 KEY DEVELOPMENTS 120
11.6.5 SWOT ANALYSIS 121
11.6.6 KEY STRATEGIES 121
?
11.7 BRISTOL-MYERS SQUIBB COMPANY 122
11.7.1 COMPANY OVERVIEW 122
11.7.2 FINANCIAL OVERVIEW 123
11.7.3 PRODUCTS/SERVICES OFFERED 123
11.7.4 KEY DEVELOPMENTS 123
11.7.5 SWOT ANALYSIS 124
11.7.6 KEY STRATEGIES 124
11.8 GLAXOSMITHKLINE PLC 125
11.8.1 COMPANY OVERVIEW 125
11.8.2 FINANCIAL OVERVIEW 126
11.8.3 PRODUCTS/SERVICES OFFERED 127
11.8.4 KEY DEVELOPMENTS 127
11.8.5 SWOT ANALYSIS 127
11.8.6 KEY STRATEGIES 128
11.9 DR. REDDY’S LABORATORIES LTD 129
11.9.1 COMPANY OVERVIEW 129
11.9.2 FINANCIAL OVERVIEW 130
11.9.3 PRODUCTS/SERVICES OFFERED 130
11.9.4 KEY DEVELOPMENTS 131
11.9.5 SWOT ANALYSIS 131
11.9.6 KEY STRATEGIES 131
11.10 GLENMARK PHARMACEUTICALS LIMITED 132
11.10.1 COMPANY OVERVIEW 132
11.10.2 FINANCIAL OVERVIEW 133
11.10.3 PRODUCTS/SERVICES OFFERED 134
11.10.4 KEY DEVELOPMENTS 134
11.10.5 SWOT ANALYSIS 135
11.10.6 KEY STRATEGIES 135
12 APPENDIX
12.1 REFERENCES 136
12.2 RELATED REPORTS 136
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 16
2.2 RESEARCH OBJECTIVE 16
2.3 MARKET STRUCTURE 16
2.4 ASSUMPTIONS & LIMITATIONS 17
3 RESEARCH METHODOLOGY
3.1 DATA MINING 18
3.2 SECONDARY RESEARCH 19
3.3 PRIMARY RESEARCH 19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 23
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 HIGH RATE OF EAR INFECTIONS 26
4.2.2 INCREASING EXPENDITURE BY GOVERNMENTS ACROSS THE WORLD TOWARDS HEALTHCARE 26
4.2.3 RISE IN RISK FACTORS 26
4.2.4 DRIVERS IMPACT ANALYSIS 27
4.3 RESTRAINTS 27
4.3.1 RISKS AND COMPLICATIONS OF SURGERY 27
4.3.2 EMERGENCE OF BACTERIAL RESISTANCE 27
4.3.3 RESTRAINTS IMPACT ANALYSIS 28
4.4 OPPORTUNITIES 28
4.4.1 TECHNOLOGICAL ADVANCEMENTS IN EAR INFECTION DIAGNOSIS AND SURGERY 28
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D AND DESIGNING 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION 30
5.1.4 MARKETING & SALES 30
5.2 PORTER’S FIVE FORCES MODEL 31
5.2.1 BARGAINING POWER OF SUPPLIERS 32
5.2.2 BARGAINING POWER OF BUYERS 32
5.2.3 THREAT OF NEW ENTRANTS 32
5.2.4 THREAT OF SUBSTITUTES 32
5.2.5 RIVALRY 32
5.3 IMPACT OF COVID-19 33
6 GLOBAL EAR INFECTION TREATMENT MARKET, BY TYPE
6.1 OVERVIEW 34
6.2 MIDDLE EAR 35
6.3 OUTER EAR 35
6.4 INNER EAR 36
7 GLOBAL EAR INFECTION TREATMENT MARKET, BY PATHOGEN
7.1 OVERVIEW 37
7.2 BACTERIA 38
7.3 VIRUS 38
8 GLOBAL EAR INFECTION TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW 39
8.2 SURGERY 40
8.3 MEDICATION 41
9 GLOBAL EAR INFECTION TREATMENT MARKET, BY END USER
9.1 OVERVIEW 43
9.2 HOSPITALS 44
9.3 ENT CLINICS 44
9.4 OTHERS 44
10 GLOBAL EAR INFECTION TREATMENT MARKET, BY REGION
10.1 OVERVIEW 45
10.2 AMERICAS 47
10.2.1 NORTH AMERICA 50
10.2.1.1 US 53
10.2.1.2 CANADA 55
10.2.2 SOUTH AMERICA 57
10.3 EUROPE 59
10.3.1 WESTERN EUROPE 62
10.3.1.1 GERMANY 65
10.3.1.2 FRANCE 67
10.3.1.3 UK 69
10.3.1.4 ITALY 71
10.3.1.5 SPAIN 73
10.3.1.6 REST OF WESTERN EUROPE 75
10.3.2 EASTERN EUROPE 77
10.4 ASIA-PACIFIC 79
10.4.1 CHINA 82
10.4.2 JAPAN 84
10.4.3 INDIA 86
10.4.4 AUSTRALIA 88
10.4.5 SOUTH KOREA 90
10.4.6 REST OF ASIA-PACIFIC 92
10.5 MIDDLE EAST AND AFRICA 94
10.5.1 MIDDLE EAST 97
10.5.2 AFRICA 99
11 COMPANY PROFILES
11.1 NOVARTIS INTERNATIONAL AG 101
11.1.1 COMPANY OVERVIEW 101
11.1.2 FINANCIAL OVERVIEW 102
11.1.3 PRODUCTS/SERVICES OFFERED 103
11.1.4 KEY DEVELOPMENTS 103
11.1.5 SWOT ANALYSIS 104
11.1.6 KEY STRATEGIES 104
?
11.2 SANOFI S.A. 105
11.2.1 COMPANY OVERVIEW 105
11.2.2 FINANCIAL OVERVIEW 106
11.2.3 PRODUCTS/SERVICES OFFERED 106
11.2.4 KEY DEVELOPMENTS 107
11.2.5 SWOT ANALYSIS 107
11.2.6 KEY STRATEGIES 108
11.3 JANSSEN PHARMACEUTICALS 109
11.3.1 COMPANY OVERVIEW 109
11.3.2 FINANCIAL OVERVIEW 110
11.3.3 PRODUCTS/SERVICES OFFERED 110
11.3.4 KEY DEVELOPMENTS 111
11.3.5 SWOT ANALYSIS 111
11.3.6 KEY STRATEGIES 111
11.4 PFIZER INC. 112
11.4.1 COMPANY OVERVIEW 112
11.4.2 FINANCIAL OVERVIEW 113
11.4.3 PRODUCTS/SERVICES OFFERED 113
11.4.4 KEY DEVELOPMENTS 114
11.4.5 SWOT ANALYSIS 114
11.4.6 KEY STRATEGIES 114
11.5 ABBOTT LABORATORIES 115
11.5.1 COMPANY OVERVIEW 115
11.5.2 FINANCIAL OVERVIEW 116
11.5.3 PRODUCTS/SERVICES OFFERED 116
11.5.4 KEY DEVELOPMENTS 117
11.5.5 SWOT ANALYSIS 117
11.5.6 KEY STRATEGIES 117
11.6 SUN PHARMACEUTICAL INDUSTRIES LIMITED 118
11.6.1 COMPANY OVERVIEW 118
11.6.2 FINANCIAL OVERVIEW 119
11.6.3 PRODUCTS/SERVICES OFFERED 120
11.6.4 KEY DEVELOPMENTS 120
11.6.5 SWOT ANALYSIS 121
11.6.6 KEY STRATEGIES 121
?
11.7 BRISTOL-MYERS SQUIBB COMPANY 122
11.7.1 COMPANY OVERVIEW 122
11.7.2 FINANCIAL OVERVIEW 123
11.7.3 PRODUCTS/SERVICES OFFERED 123
11.7.4 KEY DEVELOPMENTS 123
11.7.5 SWOT ANALYSIS 124
11.7.6 KEY STRATEGIES 124
11.8 GLAXOSMITHKLINE PLC 125
11.8.1 COMPANY OVERVIEW 125
11.8.2 FINANCIAL OVERVIEW 126
11.8.3 PRODUCTS/SERVICES OFFERED 127
11.8.4 KEY DEVELOPMENTS 127
11.8.5 SWOT ANALYSIS 127
11.8.6 KEY STRATEGIES 128
11.9 DR. REDDY’S LABORATORIES LTD 129
11.9.1 COMPANY OVERVIEW 129
11.9.2 FINANCIAL OVERVIEW 130
11.9.3 PRODUCTS/SERVICES OFFERED 130
11.9.4 KEY DEVELOPMENTS 131
11.9.5 SWOT ANALYSIS 131
11.9.6 KEY STRATEGIES 131
11.10 GLENMARK PHARMACEUTICALS LIMITED 132
11.10.1 COMPANY OVERVIEW 132
11.10.2 FINANCIAL OVERVIEW 133
11.10.3 PRODUCTS/SERVICES OFFERED 134
11.10.4 KEY DEVELOPMENTS 134
11.10.5 SWOT ANALYSIS 135
11.10.6 KEY STRATEGIES 135
12 APPENDIX
12.1 REFERENCES 136
12.2 RELATED REPORTS 136
